Indivior Pharmaceuticals, Inc. (INDV)

NASDAQ: INDV · Real-Time Price · USD

40.53

+0.02 (0.04%)

At close: Jul 24, 2026, 4:00 PM EDT

40.53

+0.01 (0.01%)

Pre-market: Jul 27, 2026, 4:50 AM EDT

Indivior Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	175	195	319	316	774	1,102
Short-Term Investments	-	-	1	94	119	-
Cash & Short-Term Investments	175	195	320	410	893	1,102
Cash Growth	-53.08%	-39.06%	-21.95%	-54.09%	-18.97%	28.44%
Accounts Receivable	273	253	254	254	220	202
Other Receivables	12	2	33	-	5	13
Total Trade Receivables	285	255	287	254	225	215
Inventory	152	153	167	135	114	95
Other Current Assets	55	50	52	467	27	32
Total Current Assets	667	652	827	1,266	1,259	1,444
Net Property, Plant & Equipment	179	170	139	124	85	95
Other Intangible Assets	2	2	6	13	70	82
Long-Term Investments	27	28	27	41	98	-
Other Long-Term Assets	322	350	316	316	257	211
Total Assets	1,197	1,201	1,316	1,760	1,769	1,832

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Accounts Payable	178	250	216	204	-	-
Accrued Expenses	565	624	661	1,027	303	5
Current Portion of Long-Term Debt	-	29	18	3	-	-
Current Portion of Leases	9	10	10	9	-	-
Other Current Liabilities	26	2	18	48	-9	-7
Total Current Liabilities	779	914	924	1,290	-1,019	-804
Long-Term Debt	486	290	315	237	-	-
Long-Term Leases	14	22	32	34	-	-
Other Long-Term Liabilities	62	73	383	390	-	-
Total Long-Term Liabilities	562	385	730	661	-	-
Total Liabilities	1,341	1,299	1,652	1,951	-1,019	-804

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Common Stock	-	62	62	68	68	70
Treasury Stock	-	-	-10	-23	-	-
Additional Paid-in Capital	165	112	90	88	-	-
Accumulated Other Comprehensive Income	-29	-30	-36	-30	-	-
Retained Earnings	-280	-243	-443	-295	1,303	1,438
Shareholders' Equity	-144	-98	-337	-191	51	203
Total Liabilities & Equity	1,197	1,201	1,316	1,760	-968	-601

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Total Debt	509	351	375	283	0	0
Net Cash (Debt)	-334	-156	-55	127	893	1,102
Net Cash Growth	-	-	-	-85.78%	-18.97%	28.44%
Net Cash Per Share	-12.97	-6.09	-2.07	4.63	32.12	36.26
Book Value	-144	-98	-337	-191	51	203
Book Value Per Share	-5.59	-3.83	-12.67	-6.97	1.83	6.68
Tangible Book Value	-146	-100	-343	-204	-19	121
Tangible Book Value Per Share	-5.67	-3.91	-12.89	-7.45	-0.68	3.98

SEC Filings: 10-K · 10-Q